Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-α and TGF-β1

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6813-6820

  Tripsianis, Gregory ^a   Papadopoulou, Evropi ^a   Romanidis, Konstantinos ^a   Katotomichelakis, Michael ^a   Anagnostopoulos, Kostas ^a   Kontomanolis, Emmanuel ^a   Botaitis, Sotirios ^a   Tentes, Ioannis ^a   Kortsaris, Alexandros ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

beta; 1; Breast cancer; HER 2; IL 6; Survival; TGF ; TNF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CANCER GRADING; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LUNG CARCINOMA; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892468370     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6813     Document Type: Article

References (71)

1. Aggarwal B, Vijayalekshmi R, Sung B (2009). Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res, 15, 425-30.
2. Al-Hassan A, Al-Ghurabi B, Al-Karkhi I (2012). Prognostic value of proinflammatory cytokines in breast cancer. J Biomol Res Ther, 1, 104.
3. Ali H, Mahdi N, Al-Jowher M (2012). Serum ig and cytokine levels in women with breast cancer before and after mastectomy. Med J Islamic World Acad-emy Sci, 20, 121-9.
4. Ali S, Leitzel K, Chinchilli V, et al (2002). Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem, 48, 1314-20.
5. Alsuhail R (2008). Serum level of interleukin 6 and tumor necrosis factor in Iraqi breast cancer patients. MMJ, 7, 34-6.
6. Alvarez B, Quinn L, Busquets S, et al (2002). Tumor necrosis factor-alpha exerts interleukin-6-dependent and independent effects on cultured skeletal muscle cells. Biochim Biophys Acta, 1542, 66-72.
7. Auvinen P, Lipponen P, Johansson R, et al (1995). Prognostic significance of TGF-β1 and TGF-β2 expressions in female breast cancer. Anticancer Res, 15, 2627-32.
8. Azizun-Nisa, Bhurgri Y, Raza F, Kayani N (2008). Comparison of ER, PR & HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev, 9, 553-6.
9. Badache A, Hynes N (2001). Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res, 61, 383-91.
10. Balkwill F (2002). Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev, 13, 135-41.
11. Balkwill F (2009). Tumour necrosis factor and cancer. Nat Rev Cancer, 9, 361-71.
12. Ben-Baruch A (2003). Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumormicroenvironment interactions. Breast Cancer Res, 5, 31-6.
13. Bewick M, Chadderton T, Conlon M, et al (1999). Expression of cerbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant, 24, 377-84.
14. Bloom H, Richardson W (1957). Histological grading and prognosis in breast cancer. Br J Cancer, 11, 359-77.
15. Bromberg J, Wrzeszczynska M, Devgan G, et al (1999). Stat3 as an oncogene. Cell, 98, 295-303.
16. Carney W, Neumann R, Lipton A, et al (2003). Potential utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem, 49, 1579-98.
17. Chavey C, Bibeau F, Gourgou-Bourgade S, et al (2007). Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res, 9, 15.
18. Chod J, Zavadova E, Halaska M (2008). Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol, 29, 613-6.
19. Colomer R, Llombard-Cussac A, Lluch A, et al (2004). Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER-2 extracellular domain. Ann Oncol, 15, 201-6.
20. Dave H, Shah M, Trivedi S, Shukla S (2012). Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients. Int J Biol Markers, 27, 53-9.
21. Derynck R, Goeddel D, Ulrich A, et al (1987). Synthesis of messenger RNAs for transforming growth factors a and β and the epidermal growth factor receptor by human tumors. Cancer Res, 47, 707-12.
22. Duffy M (2001). Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful. Clin Chem, 47, 624-30.
23. Duffy M (2002). Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem, 48, 1194-7.
24. Duffy M (2006). Serum tumor markers in breast cancer: are they of clinical value. Clin Chem, 52, 345-51.
25. Elston C, Ellis I, Pinder S (1999). Pathological prognostic factors in breast cancer. Crit Rev Oncol Haematol, 31, 209-23.
26. Esteva F, Cheli C, Fritsche H, et al (2005). Clinical utility of serum HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res, 7, 436-43.
27. Fehm T, Jager W, Kramer S, et al (2004). Prognostic significance of serum HER2 and CA15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res, 24, 1987-92.
28. Fisher P, Hancock B (1997). Gestational trophoblastic disease and their treatment. Cancer Treat Rev, 23, 1-16.
29. Grivennikov S, Greten F, Karin M (2010). Immunity, inflammation, and cancer. Cell, 140, 883-99.
30. Grivennikov S, Karin M (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev, 21, 11-9.
31. Grivennikov S, Karin M (2011). Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis, 70, 104-8.
32. Harris L, Liotcheva V, Broadwater G, et al (2001). Comparison of methods of meas-uring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol, 19, 1698-706.
33. Heikkilä K, Ebrahim S, Lawlor D (2008). Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer, 44, 937-45.
34. Isaacs C, Stearns V, Hayes D (2001). New prognostic factors for breast cancer. Semin Oncol, 28, 53-67.
35. Kayacan O, Karnak D, Beder S, et al (2006). Impact of TNFalpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol, 29, 328-35.
36. Knupfer H, Preiss R (2007). Significance of interleukin-6 (IL- 6) in breast cancer (review). Breast Cancer Res Treat, 102, 129-35.
37. Kong Y, Dai S, Xie X, et al (2012). High serum HER2 extracellular domain levels: correlation with a worse diseasefree survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol, 138, 275-84.
38. Köstler W, Schwab B, Singer C, et al (2004). Monitoring serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res, 10, 1618-24.
39. Lin W, Karin M (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest, 117, 1175-83.
40. Lipton A, Ali S, Leitzel K, et al (2002). Elevated serum Her-2/neu level predicts decreased response to hormone therapyin metastatic breast cancer. J Clin Oncol, 20, 1467-72.
41. Locksley R, Killeen N, Lenardo M (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104, 487-501.
42. Ma L, Yang H, Han X, et al (2012). Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer. Chinese Med J, 125, 4104-10.
43. MacEwan D (2002). TNF receptor subtype signalling: differences and cellular consequences. Cell Signal, 14, 477-92.
44. Massague J, Cheifetz S, Laiho M, et al (1992). Transforming growth factor-beta. Cancer Surv, 12, 81-103.
45. Moore R, Owens D, Stamp G, et al (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 5, 828-31.
46. Nicolini A, Carpi A, Rossi G (2006). Cytokines in breast cancer. Cytokine Growth Factor Rev, 17, 325-37.
47. Panis C, Herrera A, Victorino V, Aranome A, Cecchini R (2013). Screening of circulating TGF-β levels and its clinicopathological significance in human breast cancer. Anticancer Res, 33, 737-42.
48. Papadopoulou E, Anagnostopoulos K, Tripsianis G, et al (2008a). Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Neoplasma, 55, 229-38.
49. Papadopoulou E, Tripsianis G, Anagnostopoulos K, et al (2008b). The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma, 55, 113-21.
50. Papadopoulou E, Tripsianis G, Anagnostopoulos K, et al (2010). Significance of serum tumor necrosis factor-alpha and its interaction with HER-2 codon 655 polymorphism on breast cancer outcome. Int J Biol Markers, 25, 126-35.
51. Parker C (2004). Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol, 5, 101-6.
52. Perera M, Tsang C, Distel R, et al (2010). TGF-beta1 interactome: metastasis and beyond. Cancer Genomics Proteomics, 7, 217-29.
53. Ravishankaran P, Karunanithi R (2011). Clinical significance of preoperative serum interleukin-6 and Creactive protein level in breast cancer patients. World J Surg Oncol, 9, 18.
54. Reiss M, Barcellos-HoffM (1997). Transforming growth factorbeta in breast cancer: a working hypothesis. Breast Cancer Res Treat, 45, 81-95.
55. Ross J, Fletcher J, Bloom K, et al (2004). Targeted therapy in breast cancer: the HER-2/neu, gene and protein. Mol Cell Proteomics, 3, 379-98.
56. Rustin G (2003). Use of CA 125 to assess response to new agents in ovarian cancer trials. J Clin Oncol, 21, 187-93.
57. Samuel S, Hurta R, Kondaiach P, et al (1992). Autocrine induction of tumor protease production and invasion by a metallothionen-regulated TGF-β1. EMBO J, 11, 1599-605.
58. Samy N, Ragab H, El Maksoud N, Shaalan M (2010). Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark, 6, 63-72.
59. Sharif M, Mamoon N, Mushtaq S, Khadim M (2010). Age related association of Her-2/neu with prognostic markers in female breast carcinoma. J Coll Physicians Surg Pak, 20, 590-4.
60. Sharma R, Anker S (2002). Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol, 85, 161-71.
61. Sheen-Chen S, Chen H, Sheen C, et al (2001). Serum levels of Transforming growth factor-β1 in patients with breast cancer. Arch Surg, 136, 937-9.
62. Siegel P, Massagué J (2003). Cytostatic and apoptotic actions of TGF-β1 in homeostasis and cancer. Cancer, 3, 807-20.
63. Thomson A, Lotze M (2003). The cytokine handbook" (4th ed), Academic Press, London.
64. Todorovic-Rakovic N (2008). TGF-β and HER2/ErbB2 and Breast Cancer Progres-sion. In "Transforming Growth Factor-β in Cancer Therapy, Volume II," Humana Press, 141-51.
65. Tripsianis G, Papadopoulou E, Botaitis S, et al (2012). A Diagnostic and prognostic significance of serum IL-6 levels in breast cancer. JP J Biostatistics, 1-2, 59-77.
66. Ueki N, Nakazato M, Ohkawa T, et al (1992). Excessive production of transforming growth factor-β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta, 1137, 189-96.
67. Vilcek J, Lee T (1991). Tumour necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem, 266, 7313-16.
68. Wang S (2011). The functional crosstalk between HER2 tyrosine kinase and TGF-β signaling in breast cancer malignancy. J Signal Transduction, 2011, 804236.
69. Wang X, Shao X, Chen Z, et al (2012). Circulating HER2 extracellular domain (ECD) levels are associated with progression-free survival in metastatic breast cancer patients. Cancer Res, 72.
70. Yarden Y, Sliwkowski M (2001). Untangling the ErbB signaling network. Nat Rev Mol Cell Biol, 2, 127-37.
71. Zhou B, Hu M, Miller S, et al (2000). HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kB pathway. J Biol Chem, 275, 8027-31.